AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 11, 2023

The Delhi High Court has granted ten days’ time to the Government of India and the nation’s drug regulator to file a counter affidavit on the petitions filed by almost 28 pharma companies against the order prohibiting manufacturing, distribution and sale of 14 FDCs licensed prior to the year 1988, in the beginning of June. […]

Pharma Companies 186

Pharma Companies Licensing Licensing Sales 186

Pharmaceutical Technology

OCTOBER 21, 2022

Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers. Roche also holds an option for licensing second arenaviral cancer immunotherapy.

Development 278

Development Production Licensing Licensing 278

Pharmaceutical Technology

DECEMBER 19, 2022

Innate is also eligible to receive a total of up to $1.43bn (€1.35bn) in preclinical, clinical, regulatory and commercial milestone payments and royalty payments on net sales in the future. Initially, the companies signed a research collaboration and licensing agreement in 2016 to develop and assess up to two bispecific NK cell engagers.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Pharmaceutical Technology

MAY 10, 2023

According to the US government, Gilead had repeatedly refused to license patents related to PrEP research undertaken by the Department of Health and Human Services’ (HHS) Centers for Disease Control and Prevention (CDC). This research dates to the mid-2000s when CDC scientists developed the PrEP regimen, argued the government.

Drugs 264

Drugs FDA Approval Containment Licensing 264

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions.

Sales 100

Sales Vaccine Vaccination Drugs 100

Pharmaceutical Technology

AUGUST 10, 2022

Cerevance has entered a multi-year strategic research partnership with Merck (MSD outside North America) to discover new targets for Alzheimer’s disease. Furthermore, Cerevance will simultaneously out-license a discovery-stage programme to Merck under the partnership.

Licensing 223

Licensing Licensing Sales Development 223

Pharmaceutical Technology

JANUARY 6, 2023

Dutch biotechnology company Synaffix and Amgen have entered a licensing agreement for the development of next-generation antibody-drug conjugates (ADCs). For four future programmes, Amgen will also have an option for exercising exclusive licenses for research and commercialisation.

Development 130

Development Licensing Licensing Antibody 130

pharmaphorum

JANUARY 7, 2021

Under the agreement, OBT will receive an undisclosed upfront payment and may receive receive additional payments based on the achievement of discovery, clinical, and regulatory milestones, as well as royalties on any sales coming down the line. The post Oxford BioTherapeutics to research cell therapies for Gilead’s Kite appeared first on.

Research 110

Research Antibody Sales Development 110

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.

Antibody 130

Antibody Development Drugs Licensing 130

pharmaphorum

SEPTEMBER 2, 2020

Dr William Lee, Gilead’s executive vice president of research, said the drug “has the potential to be the first in a new class of therapies as a treatment for people with both solid tumours and hematological malignancies.”. The post Gilead licenses Jounce immunotherapy for $800m appeared first on. In 2016 Celgene signed a $2.6

Licensing 71

Licensing Licensing Antibody Immune Response 71

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. C4T can also earn up to $357m in milestone payments and receive low to mid-double-digit percentage royalties on net sales of the product in greater China.

In-Vivo 130

In-Vivo Bioavailability In-Vitro Licensing 130

Pharmaceutical Technology

JULY 1, 2022

Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. . Antibodies comprise two variable domains, heavy and light chains.

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. Additionally, AbbVie will make tiered royalty payments based on global product sales to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

JANUARY 4, 2023

Gilead Sciences has entered a collaboration and licensing agreement with EVOQ Therapeutics to advance the latter’s technology and develop immunotherapies to treat rheumatoid arthritis (RA) and lupus. The company will also receive tiered royalties on sales of the product.

Licensing 130

Licensing Licensing Clinical Development Sales 130

Pharmaceutical Technology

FEBRUARY 3, 2023

Goldfinch Bio’s assignment estate will receive an upfront payment of $15m and is eligible for milestone payments of up to $520m for each licensed TRPC4/5 candidate, from which $410m relates to regulatory approval and commercial sales milestones. Additionally, the company will receive a royalty on net sales of each licensed product.

Licensing 130

Licensing Licensing Sales Development 130

Pharmaceutical Technology

JULY 20, 2022

Previously, only licensed and authorised physicians, advanced practice registered nurses, and physician assistants could prescribe the drug. . billion in global sales after its launch in late 2021 in the US and other countries, as per the company’s Q1 results. Paxlovid in the news.

Pharmacy 278

Pharmacy Licensing Licensing Drugs 278

XTalks

MARCH 17, 2025

Roche, a global leader in biotechnology and diagnostics, has entered into an exclusive collaboration and licensing agreement with Zealand Pharma, a specialist in innovative therapeutics, to co-develop and co-commercialize petrelintide as a potential foundational therapy for people with overweight and obesity. billion $1.4 billion $1.4

Hormones 59

Hormones Drugs Sales Insulin 59

Pharmaceutical Technology

OCTOBER 18, 2022

Under the deal, the companies will leverage MacroGenics’ DART platform to develop MGD024 as well as two further bispecific research programmes. Gilead holds an option for licensing MGD024 as a possible therapy to treat specific blood cancers, including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).

Antibody 130

Antibody Development Sales Clinical Trials 130

BioTech 365

AUGUST 10, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Pragmatism prevails for Dicerna as it looks to out-license the sales work for mixed bag nedosiran.Pragmatism prevails for Dicerna as it looks to out-license the sales work … Continue reading →

Licensing 40

Licensing Licensing Sales Research 40

Pharmaceutical Technology

AUGUST 4, 2022

The research and development (R&D) of various present and new ‘off-the-shelf’ cell therapies against targets in B-cell lymphomas, multiple myeloma and other hematologic indications are included in this alliance. This would help them co-develop further allogeneic CAR-T product candidates for current and new hematologic targets.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

Pharmaceutical Technology

MARCH 24, 2023

Under the terms of the deal, Moderna has purchased an option to license ctLNP and closed-ended DNA (ceDNA) technology from Generation Bio. Moderna will have an additional option to license a third programme targeting either immune cells or the liver.

Genetics 130

Genetics Medicine Development In-Vivo 130

Pharmaceutical Technology

JUNE 15, 2023

The deal gives Astellas the option to exclusively license its rights for clinical development and commercialisation for any protein degrader compounds developed within the lead programme. Astellas could pay Cullgen up to $85m upon using its license option regarding the deal.

Protein 130

Protein Development Licensing Licensing 130

XTalks

DECEMBER 18, 2024

Vale, has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF1, in the pathophysiology of congenital adrenal hyperplasia, said Kyle W. Neurocrines hit drug generated $613 million in sales during the third quarter and is projected to reach $2.3

Genetics 116

Genetics Hormones Trials Drugs 116

Pharmaceutical Technology

FEBRUARY 22, 2023

Spanish pharmaceutical firm Ferrer and Swiss biotechnology firm Asceneuron have signed a licensing agreement for the latter’s O-GlcNAcase inhibitor, ASN90, to treat progressive supranuclear palsy (PSP). Additionally, Asceneuron is eligible for tiered double-digit royalties on ASN90’s global net sales.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

Pharmaceutical Technology

AUGUST 1, 2022

As a result, multiple vaccines, including Pfizer /BioNTech’s mRNA vaccine, Comirnaty, were licensed for use within a year of development beginning. For this, it will be necessary for governments to establish substantial incentive schemes to encourage pharmaceutical companies to invest more time, effort and money into antibiotic research.

Vaccine 234

Vaccine Vaccination Bacteria Life Science 234

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. The pharma will also pay tiered royalties on commercial net sales of the antibody.

Antibody 98

Antibody Trials Licensing Licensing 98

Pharmaceutical Technology

MAY 16, 2023

Emergent will also hand over San Diego, California-based research facilities (focused on the Chikungunya vaccine candidate), a Swiss-based biologics manufacturing facility, and the EU/US-based commercial operations. Following the completion of the deal, Bavarian Nordic now boasts the only oral vaccine licensed by the U.S.

Vaccine 130

Vaccine Vaccination Licensing Licensing 130

pharmaphorum

JANUARY 29, 2021

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. The post Lilly adds to pain pipeline with Asahi Kasei licensing deal appeared first on.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

Pharmaceutical Technology

AUGUST 16, 2022

Of this amount, Horizon plans to recognise research and development (R&D) costs of nearly $32.5m Q32 will also receive tiered royalty payments on net sales. in the third quarter of this year and the remaining funds next year. A fully human anti-IL-7R?

Development 130

Development Clinical Trials Clinical Trials Regulation 130

The Pharma Data

MAY 13, 2021

Product Name: Total Dental Health ebook sales page | Health Guru Mike. Click here to get Total Dental Health ebook sales page | Health Guru Mike at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

Sales 52

Sales Production Licensing Licensing 52

The Pharma Data

NOVEMBER 15, 2020

. Lead Pharma may receive payments of up to €260 million plus royalties on sales. In this single target research collaboration Lead Pharma and Roche will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for further development and global commercialization.

Licensing 52

Licensing Licensing Development Research 52

pharmaphorum

FEBRUARY 12, 2021

The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets around the world and had sales of around $140 million last year.

Drugs 111

Drugs Sales Marketing Pharma Companies 111

XTalks

JANUARY 29, 2021

Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. Merck’s Keytruda ($7.2B) and BMS’s Opdivo ($1.8B) hold the number 2 and number 11 spots, respectively, in annual sales of the top oncology products. Keytruda (Pembrolizumab) and Opdivo (Nivolumab). Celltrion’s Herceptin biosimilar, Truxima).

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

XTalks

APRIL 3, 2025

Researchers randomized participants to receive varying doses of lepodisiran or a placebo. Ruth Gimeno, Eli Lillys vice president of Diabetes, Obesity and Cardiometabolic Research, emphasized the potential of lepodisiran to provide long-term benefits with infrequent dosing. Additionally, Lp(a) levels remained 91.0%

Trials 59

Trials Clinical Trials Clinical Trials Genetics 59

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. The company will also receive tiered global net sales royalties.

Development 130

Development Antibody Licensing Licensing 130

Pharmaceutical Technology

MAY 3, 2023

BrightPath Biotherapeutics and Artisan Bio have signed a research and licensing agreement to expedite the former’s allogeneic next-generation invariant natural killer T (iNKT) cell therapies to clinic. The company will also receive net sales milestones and royalties on future products.

Gene Therapy 130

Gene Therapy Gene Engineer Development 130

pharmaphorum

NOVEMBER 18, 2022

have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the treatment of cancer. Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies.

Antibody 105

Antibody Sales Development Licensing 105